Why Is XP Power Up Today?

XP Power Limited shares rose 1.46% today to around 2,090.00p, as investors responded to mounting evidence that the power control solutions specialist is riding a broad-based recovery across its semiconductor, industrial and healthcare end markets.

The move builds on a strong H1 2026 interim results announcement in which order intake surged sharply, supporting management's confidence in robust Revenue growth through the second half of the year.

Key Highlights

XP Power's H1 2026 results showed order intake up 48% to £167.2 million (55% at constant currency), with a book-to-bill ratio of 1.53x, up from 1.02x a year earlier. Revenue was broadly flat at £109.1 million, up 2% at constant currency, while adjusted operating profit rose 79% to £8.6 million.

Gross Margin expanded by 450 basis points to 45.9%, and adjusted profit before tax jumped to £5.1 million from £0.8 million a year earlier. The order book expanded to £173.9 million, including £135 million of firm orders scheduled for delivery in the second half.

About XP Power Limited

XP Power designs, manufactures and distributes power converters — critical components that convert mains electricity into stable, usable direct current — for original equipment manufacturers across the Semiconductor Manufacturing Equipment, Industrial Technology and Healthcare sectors.

With around 2,100 employees, 22 manufacturing and design sites, and roughly 2,500 active customers, XP Power's products are typically designed into customer programmes with revenue annuities lasting five to seven years, giving the Business strong long-term revenue visibility once a design win is secured.

Key Reasons Behind Today's Rally

Today's gain reflects growing confidence that the semiconductor manufacturing equipment cycle has turned decisively higher. Chief executive Gavin Griggs described the order recovery as broad-based across sectors and regions, with semiconductor manufacturing equipment particularly strong as customers begin investing for what the company expects to be a multi-year wafer-fabrication expansion cycle.

Industrial technology orders rose 22% and healthcare orders increased 25%, indicating that the destocking cycle that had weighed on Demand in these end markets has now ended, adding further breadth to the recovery beyond semiconductor capex alone.

Order Book Underpins Second-Half Growth

With £135 million of firm orders scheduled for delivery in H2 2026 out of a total order book of £173.9 million, XP Power has strong near-term revenue visibility, supporting management's guidance for robust revenue growth in the second half despite a flattish first half.

Revenue growth in H1 was restrained by two specific factors: the expiry of US export licences governing RF sales into China, and a weaker US dollar at reported exchange rates. Industrial technology revenue rose 9% at constant currency, while healthcare revenue declined 13% due to programme timing, though management expects healthcare to return to growth in H2.

Structural Growth Drivers Remain Intact

Beyond the current cyclical recovery, XP Power's exposure to structural growth themes — including data-centre power demand, semiconductor capacity expansion, and increasingly complex power requirements in healthcare devices — supports a longer-term growth narrative for the business.

Management highlighted particularly strong demand for the company's more technically complex product categories and technology solutions projects, reflecting a deliberate strategy of investing in the product offering to maintain Competitive Advantage against both large global industrial players and lower-cost Asian manufacturers.

Risks

XP Power's revenue is exposed to cyclicality in its key end markets, particularly semiconductor manufacturing equipment, which has historically experienced pronounced boom-and-bust Capital Expenditure cycles. A Reversal in the current capex upcycle would weigh on order intake.

The group's exit from the China semiconductor market and the expiry of relevant export licences have already dampened Asian revenue, which declined 11% in H1 2026, highlighting ongoing geopolitical and trade-policy risk. Customer concentration, with the top 30 clients representing around half of group revenue, is a further consideration.

Valuation

XP Power's valuation reflects a business emerging from a challenging period of destocking and semiconductor sector weakness into a period of broad-based order recovery. The strong book-to-bill ratio and order book visibility support confidence in near-term Earnings growth.

The key valuation debate centres on the durability of the current semiconductor capex upcycle and whether XP Power can continue converting order growth into margin expansion, particularly given historical Volatility in gross margins linked to product mix and component costs.

What Investors Should Watch Next

Investors should monitor order intake trends across all three end markets, the pace of margin recovery, and progress converting the substantial order book into delivered, recognised revenue in the second half of 2026.

Developments in US-China trade policy affecting semiconductor equipment exports, and the healthcare segment's expected return to growth, will also be important signposts.

Conclusion

XP Power's 1.46% gain today reflects growing conviction that the company is at the early stages of a multi-year recovery cycle, driven by renewed semiconductor manufacturing equipment capital expenditure alongside the end of destocking in industrial and healthcare markets.

With a substantially strengthened order book, expanding margins and structural exposure to growing power demand across data centres, semiconductors and healthcare devices, XP Power appears well positioned for a stronger second half, though cyclicality in its core end markets remains an ever-present risk.